AstraZeneca: Imfinzi approved for lung cancer in China

(CercleFinance.com) - AstraZeneca has received marketing authorisation from China's regulators for its Imfinzi immunotherapy for the treatment of patients with unresectable, stage III non-small cell lung cancer, the company said on Thursday.


According to phase III results, Imfinzi reduced the risk of death by 32% and prolonged the time patients lived without disease progression or death by more than 11 months.

More than one-third of the world's lung cancer diagnoses and deaths occur in China.

Copyright (c) 2019 CercleFinance.com. All rights reserved.